Decoupling SARS-CoV-2 ORF6 localization and interferon antagonism
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Like many pathogenic viruses, SARS-CoV-2 must overcome interferon (IFN)-mediated host defenses for infection establishment. To achieve this, SARS-CoV-2 deploys overlapping mechanisms to antagonize IFN production and signaling. The strongest IFN antagonist is the accessory protein ORF6, which localizes to multiple membranous compartments, including the nuclear envelope, where it directly binds nuclear pore component Nup98–Rae1 to inhibit nuclear translocation of activated STAT1 and IRF3 transcription factors. However, this direct cause-and-effect relationship between ORF6 localization and IFN antagonism has yet to be explored experimentally. Here, we use extensive mutagenesis studies to define the structural determinants required for steady-state localization and demonstrate that mis-localized ORF6 variants still potently inhibit nuclear trafficking and IFN signaling. Additionally, expression of a peptide that mimics the ORF6–Nup98 interaction domain robustly blocked nuclear trafficking. Furthermore, pharmacologic and mutational approaches combined to suggest that ORF6 is likely a peripheral membrane protein, as opposed to being a transmembrane protein as previously speculated. Thus, ORF6 localization and IFN antagonism are independent activities, which raises the possibility that ORF6 may have additional functions within membrane networks to enhance virus replication.
This article has an associated First Person interview with the first author of the paper.
Article activity feed
-
-
SciScore for 10.1101/2021.12.06.471415: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources After blocking, samples were incubated with primary anti-STAT1 antibody (Cell Signaling Technology, 9172) in PBST with 5% BSA overnight at 4 degrees. anti-STAT1suggested: NoneThe next day, samples were washed 3 times with PBS and then incubated with secondary anti-Rabbit-AlexaFluor488 (Cell Signaling Technology, 4412) and anti-mCherry-AlexaFluor594 (Invitrogen #M11240) antibodies in PBS with 5% BSA for 1 hour at room temperature. anti-Rabbit-AlexaFluor488 ( Cell Signaling Technology , …SciScore for 10.1101/2021.12.06.471415: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources After blocking, samples were incubated with primary anti-STAT1 antibody (Cell Signaling Technology, 9172) in PBST with 5% BSA overnight at 4 degrees. anti-STAT1suggested: NoneThe next day, samples were washed 3 times with PBS and then incubated with secondary anti-Rabbit-AlexaFluor488 (Cell Signaling Technology, 4412) and anti-mCherry-AlexaFluor594 (Invitrogen #M11240) antibodies in PBS with 5% BSA for 1 hour at room temperature. anti-Rabbit-AlexaFluor488 ( Cell Signaling Technology , 4412 )suggested: Noneanti-mCherry-AlexaFluor594suggested: NoneExperimental Models: Cell Lines Sentences Resources To generate the A549 eGFP-KPNA2 stable cell line, roughly 250,000 HEK293FT cells in a 6-well plate were transfected with a pQCXIH retroviral vector containing the eGFP-KPNA2 expression cassette, an MLV-GagPol packaging vector, and a VSV-G vector. A549 eGFP-KPNA2suggested: NoneHEK293FTsuggested: RRID:CVCL_6911)Media was harvested 48 hours post-transfection and frozen at −80°C for 4-6 hours, thawed and centrifuged at 1500 x g, and overlaid on A549 cells. A549suggested: NCI-DTP Cat# A549, RRID:CVCL_0023)In addition, localization experiments were carried out using HeLa cells as they are routinely used for microscopy experiments and localization studies due to their morphological characteristics. HeLasuggested: CLS Cat# 300194/p772_HeLa, RRID:CVCL_0030)Recombinant DNA Sentences Resources To generate the A549 eGFP-KPNA2 stable cell line, roughly 250,000 HEK293FT cells in a 6-well plate were transfected with a pQCXIH retroviral vector containing the eGFP-KPNA2 expression cassette, an MLV-GagPol packaging vector, and a VSV-G vector. pQCXIHsuggested: RRID:Addgene_37104)VSV-Gsuggested: RRID:Addgene_138479)The IFNβ reporter construct was generated by cloning an IFN responsive promoter element upstream of eGFP in the pcDNA-5TO expression vector and the constitutively active RIG-I mutant vector was generated by cloning RIG-I amino acids 1-242 into an mTagBFP2-T2A-expression cassette in a lentiviral vector. pcDNA-5TOsuggested: NoneRIG-Isuggested: NoneSoftware and Algorithms Sentences Resources At 48 hours post-transfection, eGFP fluorescence was quantified (ImageJ software) and then graphed with Prism 6.0 (GraphPad ImageJsuggested: (ImageJ, RRID:SCR_003070)Prismsuggested: (PRISM, RRID:SCR_005375)For quantification of nuclear fluorescence, individual cells expressing the indicated ORF6 proteins were scored for KPNA2 or STAT1 localization by dividing the nuclear fluorescence intensity by the cytoplasmic fluorescence intensity (n=50 for KPNA2 and n=25 for STAT1), and then graphed with Prism 6.0 (GraphPad Software). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
